VULNERABILITY OF THE IMMATURE RAT BRAIN TO PHENYLACETATE INTOXICATION: POSTNATAL DEVELOPMENT OF THE DETOXICATION MECHANISM

Phenylacetate is not excreted to any significant extent as the free acid in rat urine, but must be metabolized in the liver and kidney, first to phenylacetyl-CoA, then to phenylacetylglycine. One hour after [¹⁴C]phenylacetate loading, the radioactivity in the liver and kidneys of the young rat could all be accounted for as unchanged phenylacetate (50-5573, phenylacetylglycine (35–40%), and phenylacetyl-CoA (5–8%). In the brain, the radioactivity was present mainly as phenylacetate (82–90%); only 10–18% was found as phenylacetyl-CoA. The formation of phenylacetyl-CoA appeared to be the rate limiting step in the clearance of phenylacetate. In the urine at least 95% of the radioactivity was present as phenylacetylglycine, less than 1% as phenylacetate, and 3–4% as phenylacetyl-CoA. The concentration of phenylacetylglycine in the urine was therefore used as a measure of the in vivo rate of phenylacetatc clearance. This detoxication process was found to develop postnatally. The formation of phenylacetylglycine was barely detecrabie in the newborn rat and remained relatively slow for about 2 weeks. During the third week a large increase in enzymatic activity, approx 40% occurred. Adult level of activity was reached in the 40 day old rat. The extremely slow rate of detoxication in the newborn animal was reflected in the persistence of high concentrations of phenylacetate in the tissues. The relevance of our findings to human phenyl-ketonuria is discussed     

Occurrence of 5''-Deoxy-5''-Methylthioadenosine Phosphorylase in the Mammalian CNS: Distribution and Kinetic Studies on the Rat Brain Enzyme

5'-Deoxy-5'-methylthioadenosine (MTA) phosphorylase catalyzes the cleavage of MTA, a secondary product of polyamine biosynthesis, to 5-methylthioribose-1-phosphate and adenine. The occurrence and the general properties of the enzyme were studied in mammalian brain with the following results. (1) Cerebral tissues contained levels of MTA phosphorylase that were comparable to those occurring in other mammalian tissues. (2) Interspecies differences in the enzyme distribution were quite limited, with the highest specific activity values observed in pig brain. Moreover, the enzyme seemed to be generally more concentrated in the cerebellar fractions. (3) Rat brain MTA phosphorylase was highly localized in the cellular soluble fraction. In the first days of rat life, its specific activity in the whole brain was observed to decline significantly from a value of 17.6 units/mg at 1-5 days of age to 13.7 units/mg at 6-10 days of age, remaining then fairly constant up to maturity. (4) Kinetic studies performed with the soluble enzyme extracted from rat brain showed: a pH optimum of 7.4; a Km value for MTA of about 10 microM; an inhibitory effect of the MTA analog 5'-deoxy-5'-isobutylthioadenosine; and a remarkable resistance of the enzyme to heat treatment.     

Phenylacetate and the enduring behavioral deficit in experimental phenylketonuria

Phenylacetate, a metabolite derived from phenylalanine, is clearly associated with brain dysfunction in simulated phenylketonuria. Injections of phenylacetate, phenylethylamine, or p-chlorophenylalanine + L-phenylalanine, all yielding similar concentrations of phenylacetate in the rat brain during post-natal development, induced similar behavioral deficits: hypoactivity in an open field and poor performance in both a water maze and shuttle box. In contrast, animals treated with the other major metabolites of phenylalanine, phenylpyruvate, phenyllactate and mandelate, during the same developmental period displayed normal behavior.     

Postnatal Changes in the Activity Ratio of Specific and Nonspecific Cholinesterases from Neuronal Perikarya

Abstract: A soluble fraction from rat brain neuronal perikarya was shown to contain both the specific and nonspecific forms of the enzyme acetylcholines-terase (EC's 3.1.1.7. and 3.1.1.8., respectively). The ratio of the enzyme activities varied along the course of brain development: the nonspecific form being predominant from 1 to 15 days of age and the specific one showing the pattern of rising activity from day 15 onward. We suggest a possible relationship between this changing in cholinesterase activities and the establishment of synapses within the rat cerebral cortex.     

The association of the sulphogalactosylglycerolipid of rat brain with myelination

The sulphogalactosylglycerolipid of rat brain is closely associated with the process of myelination, as demonstrated by the following observations. 1. The lipid is barely detectable in rat brain before 10 days of age, accumulates rapidly between age 10 and 25 days, and remains relatively constant in amount (between 0.3 and 0.4mumol per brain) thereafter into adult life. 2. The activity of adenosine 3'-phosphate 5'-sulphatophosphate-galactosyldiacylglycerol sulphotransferase is almost absent before 10 days of age, attains a maximum at age 20 days, and slowly decreases thereafter with increasing age. This developmental pattern correlates well with that of other myelin-specific metabolites. 3. Both the concentration of the sulphogalactosylglycerolipid and the activity of sulphotransferase are greatly decreased in the non-myelinating jimpy mouse. 4. The myelin fraction of rat brain contains most of the sulphogalactosylglycerolipid. The lipid occurs in a diacyl and an alkylacyl form. Determinations of the relative amount of each type in brain showed about a 1:1 mixture in both 21-day-old and adult rats. Rats injected with H(2) (35)SO(4) at 20 days of age lost (35)S from the diacyl form at a higher rate than from the alkylacyl compound over a 21-day period. These data suggest that the diacyl form has a higher turnover than the alkylacyl derivative. The percentage of the total sulpholipid content of brain contributed by the sulphogalactosylglycerolipid is 16% in 21-day-old rats and 8.4% in adult rats.     

Monosodium L-glutamate-induced convulsions: temporary alteration in blood-brain barrier permeability to plasma proteins.

Monosodium L-glutamate (MSG), a commonly used food additive, induces convulsive disorders in rats. A reversible change in the cerebrovascular permeability of plasma proteins occurs during convulsions induced by the intraperitoneal administration of 4.0 g/kg of MSG to the neonatal rat. During MSG-induced seizures, but not before or after, trypan blue dye enters into the brain tissues, whereas no dye penetration occurs in control rats receiving saline. The frequency of the incidence of MSG-induced convulsions is inversely proportional to the age of the animal. It decreases with the age of the rat. By 42 days of age no substantial seizure activity of dye penetration into the brain tissue occurs in MSG-treated rats. Histological examination indicates that seizure activity is not correlated with characteristic periventricular-arcuate area lesions known to be induced in neonates by parenteral MSG administration. No hypothalamic damage was observed in MSG-treated rats older than 10 days of age.     

ADENOSYLMETHIONINE DECARBOXYLASE IN DEVELOPING RAT BRAIN

Adenosylmethionine decarboxylase from rat brain has been found to be similar to the same enzyme isolated from other rat tissues in regard to kinetic parameters, pH optimum, putrescine requirement, and subcellular location. Evidence is presented that pyridoxal phosphate is not the functional cofactor in enzymatic decarboxylation by the rat brain preparation. The capacity for spermidine synthesis in developing rat brain was determined by measurement of the activity of adenosylmethionine decarboxylase. The activity increased dramatically after 10 days of postnatal age. This increase occurred after the period of maximum nucleic acid synthesis, an observation which suggests that spermidine may have a role in the functional development of the brain.     

High incorporation of dietary 1-O-heptadecyl glycerol into tissue plasmalogens of young rats

When 1-O-heptadecyl-rac-glycerol was fed (20 mg/g of food) to 19-day-old rats for 10 days, a high incorporation of the heptadecyl group into the 1-O-alk-1'-enyl group of ethanolamine plasmalogens of all tissues was observed. For example, 62% of the alkenyl groups from liver plasmalogen was of the 17:0 variety. The analogous values for other tissues were 62% in kidney, 57% in lung, 57% in heart, 50% in intestine, 43% in erythrocytes, 25% in testis and 8% in brain. The corresponding figures in the control rats (fed normal rat chow) were only 2-3% of 17:0 for all tissues. Available evidence indicates that dietary 1-O-heptadecyl-sn-glycerol is utilized to form tissue plasmalogens without the cleavage of the ether bond. The relevance of these results to the possible dietary ether lipid therapy of patients suffering from congenital ether lipid deficiency is discussed.     

Age-Related Decline in DNA Polymerase β Activity in Rat Brain and Tissues

Fidelity of DNA polymerases is vital for maintaining genomic integrity. Deficient DNA repair leads to age related disorders or cancer. If the age at which the decline in activity of predominant DNA repair enzymes starts is identified, and the deficient proteins supplemented, then the manifestation of these diseases can be delayed promoting healthy aging. DNA polymerase β (pol β) is a predominant repair enzyme in brain. DNA pol β activity declines with age in rat brain/neurons but the exact age during the life time of rat when this decline begins is not known, and comparison of this activity was not made between post mitotic and proliferating tissues therefore the pattern of pol β with age was studied in rat brain and tissues. The decline in pol β activity started between 30 and 45 days postnatal in all the tissues. Post mitotic tissues showed pronounced decline than the proliferating tissues.     

THE EFFECTS OF PHENYLKETONURIC AND OTHER METABOLITES ON SULFATED GALACTOCEREBROSIDE SYNTHESIS IN VIVO AND IN CULTURE

Abstract— Sulfated galactocerebroside synthesis was examined in vitro in mouse spinal cord cultures. This system permitted the study of the effects of phenylketonuric metabolites upon synthesis of a specific myelin component, sulfatide, formed early in postnatal development in mice. A significant reduction of Na₂³⁵SO₄ incorporation into myelin sulfatide was observed when spinal cord cultures were grown in the presence of 1000 μm -l -phenylalanine and 500 μm -phenylpyruvate (51 and 700%, respectively). No reduction was observed with β-phenyllactate (300 μm and) phenylacetate (250 μm ). Light microscopy indicated that the phenylpyruvate and phenylalanine treated cultures were less extensively myelinated compared to control and β-phenyllactate or phenylacetate treated cultures. The reduction of sulfatide synthesis by phenylpyruvate was shown to be reversible. Intracerebral bilateral injections (8 μg) of l -phenylalanine, phenylpyruvate, α-ketobutyrate, α-ketoisocaproate, α-ketoisovalerate, β-phenyllactate, and phenylacetate in mice 8–15 days old, followed by i.p. administration of radioactive sulfate, resulted in significantly reduced incorporation (all P < 0.05) of sulfate into brain sulfatides with all compounds tested with the exception of β-phenyllactate and phenylacetate. In adult mouse, phenylpyruvate treatment also resulted in a significant decrease in labelling of brain sulfatide. The effects of phenylpyruvate and other metabolites upon pyruvate oxidation in mouse brain homogenates were examined by measuring ¹⁴CO₂ release from [1-¹⁴C]pyruvate. Both phenylpyruvate and α-ketoisocaproate at 1 × 10^-3 resulted in a decrease in ¹⁴CO₂ produced, while phenylacetate and β-phenyllactate had no effect. Sulfate incorporation into sulfatide was reduced by α-ketoisocaproate and phenylpyruvate, and to a lesser extent by phenylalanine, α-ketobutyrate, and α-ketoisovalerate. Phenyllactate and phenylacetate had no effect, either in vivo, or in culture. This order of effectiveness may be related in part to the effects of these compounds on pyruvate oxidation.     

Myelination in rat brain: changes in myelin composition during brain maturation

Abstract— Myelin was isolated from rat brains during development by a procedure giving fractions of constant purity at all ages. The lipid composition of these fractions and of whole brains of littermates was determined. The amount of myelin recovered per brain was a nearly linear function of the logarithm of age from the youngest (15 days) to the oldest (425 days) animals studied. With the exception of the earliest age point, the isolated myelin accounted for approximately 40 per cent of total brain galactolipid, evidence that a constant fraction (calculated to be 60 per cent) of myelin was recovered at all ages. Although the lipid-protein ratio of the myelin was constant with age, marked changes were seen in the amounts of cerebroside, sulphatide, phosphatidylcholine and desmosterol. The total galactolipid increased from 21 per cent of the total lipid at age 15 days to about 31 per cent at maturity. Phosphatidylcholine decreased from 17 to 11 per cent during the same period. Desmosterol decreased from 2.5 per cent of the total sterol to 0.2-0.3 per cent. All of these changes were complete between 2 and 5 months of age; no other ‘lower phase’ lipids showed significant changes with age. Although qualitatively similar to those reported by others, the changes differed in magnitude, with more stability in the levels of cholesterol and phosphatidalethanolamine with development. A sensitive indicator of the maturation of myelin was the mole ratio galactolipid/phosphatidylcholine, which varied from 1.2 at age 15 days to 2.8 at maturity. The maximum rate of myelination occurred at 20 days of postnatal age when myelin was deposited at the rate of 3.5 mg day^?1 brain^?1. However, at this age the rat brain had only 15 per cent of its eventual complement of myelin. The rate of accumulation of cerebroside in the whole brain paralleled that of myelin, and was the only lipid to show this relationship. Myelin deposition appeared to be almost solely responsible for the continued increase in brain weight after about 100 days of age.     

Tissue distribution and developmental expression of protein kinase C isozymes

Protein kinase C is a ubiquitous enzyme found in a variety of mammalian tissues and is especially highly enriched in brain and lymphoid organs. Based on biochemical and immunological analyses, we have identified three types of protein kinase C isozyme (designated types I-III) from rat brain. Monospecific antibodies against each of the protein kinase C isozymes were prepared for the determination of tissue distribution, subcellular localization, and developmental changes of these enzymes. The various protein kinase C isozymes were found to be distinctively distributed in different tissues: the type I enzyme in brain; the type II enzyme in brain, pituitary and pineal glands, spleen, thymus, retina, lung, and intestine; and the type III enzyme in brain, pineal gland, retina, and spleen. The rat brain enzymes were differentially distributed in different subcellular fractions. The type I enzyme appeared to be most lipophilic and was recovered mostly in the particulate fractions (80-90%) regardless of the EGTA- or Ca2+-containing buffer used in the homogenization. Significant amounts (30-40%) of the type II and III enzymes were recovered in the cytosolic fraction with EGTA-containing buffer. The expressions of different protein kinase C isozymes appear to be differently controlled during development. In rat brain, both type II and III enzymes were found to increase progressively from 3 days before birth up to 2-3 weeks of age and remained constant thereafter. However, the expression of the type I enzyme displayed a different developmental pattern; it was very low within 1 week, and an abrupt increase was observed between 2 and 3 weeks of age. In thymus, the type II enzyme was found to be maximal shortly after birth; whereas the same kinase in spleen was very low within 2 weeks of age, and a significant increase was observed between 2 and 3 weeks. These results demonstrate that protein kinase C isozymes are distinctively distributed in different tissues and subcellular locales and that their expressions are controlled differently during development.     

UDP-galactose:glycoprotein galactosyltransferase activity in tissues of developing rat

UDP-galactose:glycoprotein galactosyltransferase activity has been measured in several tissues of the rat, ranging in age from 16 days embryo to 35 days postnatal. The enzyme activity was found to be high in fetal liver, lungs, and brain tissues but the concentration decreased with gestational age with no further changes after birth. The enzyme activity in the serum of newborns was higher than in pregnant and nonpregnant adult rats. There was no qualitative difference (optimum pH, cation requirements, affinity for the substrate UDP-galactose, or requirement for Triton X-100) between the enzyme from embryonic liver and that from adult rats. During the embryonic stage nearly half of the enzyme activity was localized in a plasma membrane-rich fraction and only a minor part in the microsomal fraction, while in the adult most of the activity was present in the microsomal fraction. Under certain conditions of assay the incorporation of galactose into glycoprotein in liver homogenates was greatly stimulated by CDP-choline or ATP. However, CDP-choline showed a considerably greater effect than ATP at 5 days after birth but this effect could be eliminated by solubilizing the homogenates in deoxycholate.     

Superoxide dismutase in normal and malignant tissues in different species.

1. Superoxide dismutase (superoxide: superoxide oxido-reductase, E.C. 1.15.1.1) in different species was determined quantitatively and qualitatively. Although quantitative differences were minor, there were significant differences in the isoenzyme patterns among the species. 2. No quantitative differences were found in superoxide dismutase (SOD) activities in the brains of mice between 1 and 23 days of age. The mitochondrial isoenzyme increased with age, attaining maximal levels between 9 and 12 days. In the six, regions of adult rat brain studied, highest values of SOD were found in the hypothalamus and lowest in the cortex. 3. SOD levels generally were lower in several transplantable mouse and rat tumors than in normal tissues of these species. Mn-SOD was not detected in the tumors studied by the methods employed.     

Developmental profile of three enolase isozymes in rat brain determination from one-cell embryo to adult brain

Levels of three enolase isozymes (αα, αγ and γγ) were determined in rat tissues from one-cell embryo to adult brain with a sensitive enzyme immunoassay system. Each embryo of the early stage (gestational age, 0–3 days) contained about 5 × 10^?17 mol of αα enolase. The nervous system-specific αγ and γγ enolases would be detected in the embryos of 6–8 days, which contain no histologically recognizable neurones. The 8-day embryos contained 4.3 × 10^?17 and 3.4 × 10^?16 mol of αγ and γγ enolases. Amounts of all the three enolases were increased with growth of the embryo. The nervous system-specific enolases (αγ and γγ) in the brain kept increasing until 1–2 months of postnatal age, whereas the αα enolase level in the brain was relatively constant after the 15-day embryo through the adult rat.     

αγ-Enolase in the Rat: Ontogeny and Tissue Distribution

Abstract: The rat brain enolases are dimers composed of α and γ subunits. At pH 8.6 αγ-enolase seemed to be stable, and no evidence was found for the possible formation of αγ-enolase from αα-enolase and γγ-enolase in the course of rat brain homogenization. During ontogeny of the rat forebrain, αγ-enolase was formed before γγ-enolase. The half-maximal specific concentrations were reached at postnatal days 14 and 23, respectively. The distribution of αγ- and γγ-enolase in various rat brain areas was also investigated. In all areas both forms were present. In neuroendocrine tissues αγ-enolase was present at a much higher concentration than γγ-enolase. The ratio between γγ-enolase and αγ-enolase may be indicative of the degree of neuronal maturation, a conclusion further substantiated by the high ratio observed in cerebellum and the low ratio observed in olfactory bulbs, both compared with the ratio in forebrain.     

In vivo development of brain phosphocreatine in normal and creatine-treated rabbit pups

To study the effects of creatine (Cr) on brain energy metabolism and on hypoxia-induced seizures, 5- to 30-day-old rabbit pups were given subcutaneous Cr (3 g/kg) for 3 days before exposure to 4% O2 for 8 min. In saline-treated controls, hypoxic seizures were most frequent at 15 days (80% of pups) and 20 days (60%) of age. Seizures were prevented at 15 days and reduced 60% at 20 days in Cr-treated pups. In surface coil-localized brain 31P nuclear magnetic resonance spectra, with signal from both cerebral gray (GM) and white (WM) matter, the phosphocreatine (PCr)/nucleoside triphosphate (NTP) ratio doubled between 5 and 30 days of age in controls. In all Cr-injected pups, brain PCr/NTP increased to values seen in 30-day-old controls. When spectra were acquired in predominantly GM and WM slices in vivo, the PCr/NTP ratio was very low in GM at 5 days but reached adult levels by 15 days in controls. In WM, the ratio increased steadily from 5 to 30 days of age. In Cr-injected pups, PCr/NTP increased to mature levels in WM and in GM at all ages. In conclusion, hypoxic seizures occur midway in the time course of brain PCr/NTP increase in rabbit pups as previously described in rat pups. In both altricial pups, systemic Cr increases brain PCr/NTP ratio and prevents hypoxic seizures. These results suggest that mature levels of PCr and/or Cr in brain limit EEG activation either directly or indirectly by preventing hypoxic metabolic changes.     

Developmental and Age-Related Changes in Rat Brain Glycosaminoglycans

The quantities of each major class of glycosaminoglycan were determined in rat cerebrum from postnatal day 5 to 30 months of age. Chondroitin sulphate, dermatan sulphate, heparan sulphate, heparin, and hyaluronate were found, but no keratan sulphate was detected. Large and rapid changes in glycosaminoglycan content were observed during the period of brain maturation, and thereafter relatively steady levels were maintained until after the age of 12 months. The most remarkable change in the aged rat cerebrum was the ratio by weight of hyaluronate to chondroitin sulphate, which was approximately 1:1 from postnatal day 10 to 18 months but increased to 2.6:1 by the age of 30 months. In immature rats, the proportion of nonsulphated and 6-sulphated disaccharides derived from chondroitinase AC digests of brain glycosaminoglycans was much greater than in adults. In mature rats, chondroitin sulphate was composed almost entirely of 4-sulphated disaccharide subunits. The possibility that these changes could affect the permeability properties of the cerebral extracellular space and ionic equilibria in the brain is discussed.     

Phenylacetate and brain dysfunction in experimental phenylketonuria: synaptic development

High affinity uptake of choline, GABA, norepinephrine and serotonin into synaptosomes and ganglioside content of cortices served as indices of synaptic development. Both parameters indicated that phenylacetate contributed to the retarded maturation of synapses in the cerebrum of the adult rat, previously treated with either phenylacetate or one of its precursors, phenylalanine (with p-CPA) and phenylethylamine, during the first 21 days of life. In these groups of rats, which also exhibited a pronounced deficit in learning capacity, the velocity of high affinity synaptosomal uptake of choline was reduced to a greater extent than that of GABA, and there was a profound decrease in the ganglioside content of cerebral cortex. In contrast, synaptic maturation and behavior of control and phenylpyruvate treated animals were similar. These findings lend strong support to our contention that phenylacetate, produced in excessive amounts in PKU, is most likely a primary cause of the mental retardation.